GGiantBullStocks

Agios Pharmaceuticals, Inc. (AGIO)

NASDAQ · Healthcare

$40.06+1.14%

As of Jul 20, 2026

Price history

Key statistics

Market cap
$2.62B
P/E ratio
EPS
Volume
622,645
52-week high
52-week low
Open
$39.76
Day high
$40.50
Day low
$39.76

Financial highlights

Fiscal yearRevenueNet incomeEPS
2025$54.03M-$412.78M-$7.12
2024$36.5M$673.73M$11.64
2023$26.82M-$352.09M-$6.33
2022$14.24M-$231.8M-$4.23
2021$0$1.6B$26.55

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.

CEO
Brian Goff
Employees
486
Country
US
IPO date
Jul 24, 2013

Similar stocks

Other Healthcare companies

Frequently asked questions

What is Agios Pharmaceuticals, Inc.'s stock price today?
AGIO is trading at $40.06 as of Jul 20, 2026.
What is Agios Pharmaceuticals, Inc.'s market cap?
Agios Pharmaceuticals, Inc. (AGIO) has a market capitalization of $2.62B.
Does Agios Pharmaceuticals, Inc. pay a dividend?
Agios Pharmaceuticals, Inc. did not pay a dividend in its most recent reported fiscal year.
What sector is Agios Pharmaceuticals, Inc. in?
Agios Pharmaceuticals, Inc. operates in the Healthcare sector.